Canavan Disease clinical trials at UCSF
1 research study open to eligible people
Canavan disease is a rare brain disorder. UCSF is studying a new treatment called BBP-812, which uses AAV9 gene therapy. The main goal of this trial is to test the safety and effects of this new therapy.
Showing trials for
AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
open to eligible people ages up to 30 months
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Oakland, California and other locations
Our lead scientists for Canavan Disease research studies include Alexander Fay, MD.
Last updated: